The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages 1351–1356).
This is a preview of subscription content, log in via an institution to check access.
References
Downward, J. Nat. Rev. Cancer 3, 11–22 (2003).
Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M.P. Biochim. Biophys. Acta 1784, 159–185 (2008).
Engelman, J.A. et al. Nat. Med. 14, 1351–1356 (2008).
Samuels, Y. et al. Science 304, 554 (2004).
Maira, S.M. et al. Mol. Cancer Ther. 7, 1851–1863 (2008).
Gupta, S. et al. Cell 129, 957–968 (2007).
Lim, K.H. & Counter, C.M. Cancer Cell 8, 381–392 (2005).
Davies, B.R. et al. Mol. Cancer Ther. 6, 2209–2219 (2007).
Hingorani, S.R. et al. Cancer Cell 4, 437–450 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. Targeting RAS and PI3K in lung cancer. Nat Med 14, 1315–1316 (2008). https://doi.org/10.1038/nm1208-1315
Issue Date:
DOI: https://doi.org/10.1038/nm1208-1315
- Springer Nature America, Inc.
This article is cited by
-
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
Cell Death & Differentiation (2023)
-
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Acta Pharmacologica Sinica (2023)
-
Enhanced O-GlcNAc modification induced by the RAS/MAPK/CDK1 pathway is required for SOX2 protein expression and generation of cancer stem cells
Scientific Reports (2022)
-
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
Cell Death Discovery (2020)
-
Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer
Pharmaceutical Research (2017)